Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma
Abstract
Research context
OpenAlex topics: PARP inhibition in cancer therapy · Protein Degradation and Inhibitors · CRISPR and Genetic Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics School of Pharmacy Tianjin Medical University Tianjin 300070 China
Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education) International Joint Laboratory of Ocular Diseases (Ministry of Education) Tianjin Medical University Tianjin 300070 China
Department of Systems Biology the University of Texas MD Anderson Cancer Center Houston TX 77030 USA
State Key Laboratory of Toxicology and Medical Countermeasures Beijing Institute of Pharmacology and Toxicology Beijing 100850 China
Department of Neurosurgery the Affiliated Drum Tower Hospital School of Medicine Nanjing University Nanjing 210008 China
Tianjin Key Laboratory of Ophthalmology and Visual Science Tianjin Eye Institute Tianjin Eye Hospital Tianjin 300020 China
State Key Laboratory of Medicinal Chemical Biology Nankai University Tianjin 300071 China
Department of Genetics School of Basic Medical Sciences Tianjin Medical University Tianjin 300070 China
The Shraga Segal Department of Microbiology Immunology and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 84105 Israel
National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital Tianjin 300060 China
Department of Pharmacy Tianjin Medical University General Hospital Tianjin 300052 China
Funding
National Natural Science Foundation of China · Tianjin Medical University